Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYM021 + SYM022 + SYM023
- Development stage
- Phase 1
- Lead developer
- Symphogen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SYM021 + SYM022 + SYM023 is a combination of three fully human monoclonal antibodies targeting different immune checkpoints: PD-1 (SYM021), LAG-3 (SYM022), and TIM-3 (SYM023). These antibodies are intended to act synergistically by blocking multiple immune inhibitory pathways on T-cells, thus enhancing antitumor immunity. The combination is being investigated primarily for advanced solid tumors and lymphomas, with the aim of increasing immune-mediated tumor cell killing. All three antibodies are under development by Symphogen and have been studied together in phase 1 trials for safety, tolerability, and preliminary anti-tumor activity.
02
Targets
LAG3 (Lymphocyte activation Gene-3 protein)PDCD1 (Programmed cell death protein 1 receptor)HAVCR2 (T cell immunoglobulin and mucin domain-containing protein 3)
Beyond the preview
Go deeper on SYM021 + SYM022 + SYM023.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SYM021 + SYM022 + SYM023.